Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,451.23 and traded as high as GBX 1,604. Hikma Pharmaceuticals shares last traded at GBX 1,585, with a volume of 640,385 shares trading hands.

Analysts Set New Price Targets

A number of analysts recently weighed in on HIK shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 195 price objective on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Jefferies Financial Group boosted their price target on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of GBX 1,687.

Get Hikma Pharmaceuticals alerts:

View Our Latest Research Report on Hikma Pharmaceuticals

Hikma Pharmaceuticals Price Performance

The company has a market cap of £3.34 billion, a PE ratio of 8.76, a PEG ratio of 2.38 and a beta of 0.65. The company has a debt-to-equity ratio of 61.84, a current ratio of 1.82 and a quick ratio of 1.27. The stock’s 50-day moving average is GBX 1,519.52 and its 200 day moving average is GBX 1,451.23.

About Hikma Pharmaceuticals

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

Recommended Stories

• Five stocks we like better than Hikma Pharmaceuticals
• Financials Hit Record Highs as the AI Trade Unravels—Can They Keep Leading?
• Netflix’s Big Sell-Off May Be Sending the Wrong Signal
• Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
• ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.